• Tricida

  Participated · Series D · Nov 2017

  Tricida focuses on the development and commercialization of TRC101, a non-absorbed, orally dosed polymer drug designed to treat metabolic acidosis in chronic kidney disease (CKD) patients. The company has completed a Phase 1/2 double-blind, placebo-controlled trial of TRC101 and recently completed enrollment in a pivotal Phase 3 clinical trial. The results of these trials are intended to serve as the basis for a U.S. New Drug Application (NDA) submission under the FDA Accelerated Approval Program. Tricida is privately held and headquartered in South San Francisco, Calif. The company announced a $100 million venture debt facility to provide financial flexibility as it continues development of TRC101. At closing Tricida drew $25 million, with an additional $50 million available upon achievement of future milestones and a remaining $25 million subject to Hercules' approval. Tricida is a Phase 3 clinical-stage biopharmaceutical company based in South San Francisco, Calif., focused on discovery and development of non-absorbed oral drug therapies. Its lead investigational candidate, TRC101, is a first-in-class, orally administered, counterion-free, insoluble, non-absorbed polymeric drug for treating metabolic acidosis in patients with chronic kidney disease (CKD). The company is conducting TRCA-301, a randomized, double-blind, placebo-controlled Phase 3 trial expected to enroll ~210 subjects at 54 sites with a 12-week treatment period followed by a 40-week blinded extension. Proceeds from the oversubscribed $57.5 million Series D will be used to complete the pivotal TRCA-301 study. If successful, TRCA-301 is intended to serve as the pivotal trial for a U.S. New Drug Application under the FDA’s accelerated approval pathway. Tricida has raised $153.3 million to date and has completed a Phase 1/2 study whose results were presented at ASN 2017 and published in CJASN. Tricida, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies for patients with chronic kidney disease (CKD). Its lead program is TRC101, a chronic treatment for complications of renal disease. Tricida is on track to complete a first-in-human 100-patient Phase 1/2 study of TRC101 in 2016 and is preparing to discuss the safety and efficacy results with the FDA in a Type B meeting later this year. Company leadership says establishing clinical proof of concept for TRC101 is ahead of schedule. Financially, Tricida has raised $55M in a Series C, bringing total financing to $95M following earlier rounds. The company is based in South San Francisco, California. Tricida is a privately-held, pre-clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics addressing complications of renal disease. Its lead program, TRC101, is a chronic treatment candidate for complications of renal disease. The company says TRC101 is on track for an IND submission later this year. Tricida recently closed a $30M Series B financing led by existing investor OrbiMed, with participation from Sibling Capital Ventures and Limulus Venture Partners. Management highlighted rapid progress in advancing TRC101 from discovery into development. The company is based in South San Francisco, Calif., and its leadership includes CEO Gerrit Klaerner and CSO Jerry Buysse.

• Ra Pharmaceuticals

  Participated · Series B · Jul 2015

  Ra Pharmaceuticals combines insights into innate immunity with macrocycle technology to develop peptide-like therapeutics from its proprietary Extreme Diversity™ platform. Its lead molecule, RA101495, is a next-generation complement C5 inhibitor expected to enter Phase 1 clinical studies for paroxysmal nocturnal hemoglobinuria (PNH) in late 2015 and is described as a self-administered, subcutaneous product. Preclinical data demonstrated near complete inhibition of hemolysis in non-human primates. The company plans to use the proceeds of its recently completed financing to generate human proof-of-concept data for RA101495 across multiple indications and to advance multiple product candidates derived from the Extreme Diversity platform. Ra also intends to develop a broader pipeline targeting additional diseases of the complement system. The company additionally maintains a multi-target collaboration with a Merck subsidiary (MSD outside the U.S. and Canada), which has been extended.

No current team members are available.